Advertisement
CELZ vs GNPX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and GNPX is a Hold.
CELZ sees MACD Histogram crosses below signal line
CELZ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CELZ's RSI Oscillator exited the oversold zone, 31 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +12.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELZ advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.546) is normal, around the industry mean (3.498). P/E Ratio (-0.303) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GNPX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for GNPX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 32 similar instances where the indicator exited the overbought zone. In 32 of the 32 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GNPX's RSI Indicator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on GNPX as a result. In 60 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +11.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 150 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (3.498). P/E Ratio (0.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CELZ | GNPX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 91 | 93 | |
P/E GROWTH RATING 1..100 | 15 | 84 | |
SEASONALITY SCORE 1..100 | 85 | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX's Valuation (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for CELZ (83) in the null industry. This means that GNPX’s stock grew somewhat faster than CELZ’s over the last 12 months.
GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CELZ (100) in the null industry. This means that GNPX’s stock grew similarly to CELZ’s over the last 12 months.
CELZ's SMR Rating (98) in the null industry is in the same range as GNPX (100) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew similarly to GNPX’s over the last 12 months.
CELZ's Price Growth Rating (91) in the null industry is in the same range as GNPX (93) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew similarly to GNPX’s over the last 12 months.
CELZ's P/E Growth Rating (15) in the null industry is significantly better than the same rating for GNPX (84) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew significantly faster than GNPX’s over the last 12 months.
| CELZ | GNPX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 88% | N/A |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 85% | 13 days ago 76% |
| Declines ODDS (%) | 2 days ago 85% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CELZ’s FA Score shows that 1 FA rating(s) are green while GNPX’s FA Score has 0 green FA rating(s).
- CELZ’s FA Score: 1 green, 4 red.
- GNPX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CELZ’s TA Score shows that 4 TA indicator(s) are bullish while GNPX’s TA Score has 4 bullish TA indicator(s).
- CELZ’s TA Score: 4 bullish, 3 bearish.
- GNPX’s TA Score: 4 bullish, 3 bearish.
Price Growth
CELZ (@Biotechnology) experienced а -10.75% price change this week, while GNPX (@Biotechnology) price change was -9.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
CELZ is expected to report earnings on Mar 03, 2027.
GNPX is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CELZ and
Correlation & Price change
A.I.dvisor tells us that CELZ and WVE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELZ and WVE's prices will move in lockstep.
| Ticker / NAME | Correlation To CELZ | 1D Price Change % | ||
|---|---|---|---|---|
| CELZ | 100% | -1.80% | ||
| WVE - CELZ | 30% Poorly correlated | -2.01% | ||
| TRDA - CELZ | 29% Poorly correlated | +11.94% | ||
| GNPX - CELZ | 28% Poorly correlated | +1.46% | ||
| ACET - CELZ | 26% Poorly correlated | +0.33% | ||
| TCRX - CELZ | 25% Poorly correlated | +1.98% | ||
More | ||||